ArticleJournal of neurology2025
New genotype-phenotype correlations and transcriptomic findings in limb-girdle muscular dystrophy R9.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveWe aimed to comprehensively investigate the clinical, genetic, muscle imaging, and pathological characteristics of limb-girdle muscular dystrophy R9 (LGMDR9) in a large cohort of Chinese patients. In addition, we sought to delineate the muscle transcriptomic landscape of LGMDR9 which has not been investigated.
methodsIn total, 44 genetically confirmed Chinese LGMDR9 patients were enrolled. They underwent a detailed clinical, imaging, and pathological assessment, followed by customized bioinformatics analyses of genome-wide transcriptome data.
resultsLGMDR9 patients presented with heterogeneous clinical manifestations, including hyper-creatine kinase-emia without weakness (n = 15), as well as mild (n = 11), moderate (n = 7), and severe (n = 11) weakness subgroups determined by hierarchical analysis. Eleven of the 35 pathogenic FKRP variants identified in our cohort were novel, with the c.545A > G variant being the most common found in 72.7% (32/44) patients. Hierarchical analysis revealed that 15 patients harboring null variants (frameshift, nonsense, and large deletions) exhibited a more severe phenotype compared to those with missense/inframe variants in FKRP. Muscle biopsy showed a dystrophic pattern in 19 patients, necrotizing myopathy in 5 patients, and mild myopathic changes in 9 patients. Muscle magnetic resonance imaging analysis showed a concentric pattern of fatty infiltration in 60.7% (17/28) patients. Transcriptomic profiling of 12 muscle samples showed significant upregulation of genes related to inflammation/immune response and extracellular matrix remodeling (P < 0.05). Furthermore, weighted gene co-expression network analysis identified a "turquoise" module enriched in immune cell proliferation and inflammatory markers, which were strongly correlated with histopathological inflammatory scores validated by immunohistochemical staining.
conclusionOur findings indicate that null variants in FKRP may be associated with a severe phenotype. We also provide the first transcriptomic and experimental evidence of an immune-activated inflammatory microenvironment in LGMDR9 muscle tissue, which support the potential utility of immunomodulatory therapies in managing this condition.
Indexed as
Identifiers
40676230What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.